NASDAQ:OPNT

Opiant Pharmaceuticals - OPNT Stock Forecast, Price & News

$11.07

-0.53 (-4.57%)

(As of 10/5/2022 12:00 AM ET)

Add

Compare

Today's Range: $11.07
▼
$11.77
50-Day Range: $9.52
▼
$13.48
52-Week Range: $7.34
▼
$37.71

Volume: 23,111 shs
Average Volume: 14,871 shs
Market Capitalization: $57.12 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $42.00

Opiant Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 279.4% Upside
$42.00 Price Target
Short Interest: Healthy
0.40% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$60,254 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($7.40) to ($1.83) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.39 out of 5 stars

Medical Sector

230th out of 1,072 stocks

Pharmaceutical Preparations Industry

100th out of 534 stocks

3.5

Analyst's Opinion

Consensus Rating
Opiant Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $42.00, Opiant Pharmaceuticals has a forecasted upside of 279.4% from its current price of $11.07.
Amount of Analyst Coverage
Opiant Pharmaceuticals has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
0.40% of the outstanding shares of Opiant Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Opiant Pharmaceuticals has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Opiant Pharmaceuticals has recently decreased by 1.89%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Opiant Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Opiant Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for OPNT.

3.3

News and Social Media Coverage

News Sentiment
Opiant Pharmaceuticals has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Opiant Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
1 people have searched for OPNT on MarketBeat in the last 30 days.
MarketBeat Follows
2 people have added Opiant Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Opiant Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $60,254.00 in company stock.
Percentage Held by Insiders
25.15% of the stock of Opiant Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 36.12% of the stock of Opiant Pharmaceuticals is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Opiant Pharmaceuticals are expected to grow in the coming year, from ($7.40) to ($1.83) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Opiant Pharmaceuticals is -2.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Opiant Pharmaceuticals is -2.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Opiant Pharmaceuticals has a P/B Ratio of 1.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Opiant Pharmaceuticals (NASDAQ:OPNT) Stock

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California.

Receive OPNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Opiant Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

OPNT Stock News Headlines

October 5, 2022 | marketwatch.com

INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Opiant Pharmaceuticals, Inc. for Potential Breach of Fiduciary Duty Claims

August 22, 2022 | finance.yahoo.com

Opiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent with Claims Covering OPNT004 for the Treatment of Cannabinoid Hyperemesis Syndrome

August 13, 2022 | finance.yahoo.com

Analysts Just Shaved Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts Dramatically

August 11, 2022 | finance.yahoo.com

Opiant Pharmaceuticals Announces Second Quarter and First Half 2022 Financial Results and Provides Corporate Update

August 9, 2022 | finance.yahoo.com

Opiant Pharma Secures Additional BARDA Funding For Opioid Overdose Treatment

August 8, 2022 | finance.yahoo.com

Opiant Pharmaceuticals Announces Additional $2.1 Million Funding Under BARDA Contract for OPNT003, Nasal Nalmefene

August 4, 2022 | nasdaq.com

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) insiders sold US$871k worth of stock, possibly signalling a downtrend

August 2, 2022 | finance.yahoo.com

Opiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent With Claims Covering OPNT003 for the Treatment of Opioid Overdose

August 1, 2022 | finance.yahoo.com

Opiant Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022

June 9, 2022 | finance.yahoo.com

A Look At The Fair Value Of Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)

June 8, 2022 | finance.yahoo.com

Opiant Pharmaceuticals and Aptar Pharma Expand Long-Term Collaboration for the Manufacture of Unidose Nasal Spray for OPNT003, Nasal Nalmefene

June 1, 2022 | finance.yahoo.com

Opiant Pharmaceuticals Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose

May 20, 2022 | finance.yahoo.com

Opiant Pharmaceuticals to Hold Virtual 2022 Annual Shareholder Meeting on Tuesday, June 14, 2022 at 9:00am PDT

May 14, 2022 | seekingalpha.com

Opiant Pharmaceuticals, Inc. (OPNT) CEO Dr. Roger Crystal on Q1 2022 Results - Earnings Call Transcript

May 12, 2022 | finance.yahoo.com

OPNT: Positive Results for Pharmacodynamic Trial of OPNT003…

May 10, 2022 | ca.investing.com

Opiant Pharmaceuticals Posts Wider Q1 Loss

May 9, 2022 | finance.yahoo.com

Opiant Pharmaceuticals' (NASDAQ:OPNT) investors will be pleased with their solid 195% return over the last five years

May 3, 2022 | finance.yahoo.com

Opiant Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 10, 2022

April 29, 2022 | seekingalpha.com

Opiant in pact with Hikma to market opioid overdose therapy in Europe

April 28, 2022 | seekingalpha.com

Opiant opioid overdose candidate namalfene demonstrates non-inferiority to naloxone

April 28, 2022 | msn.com

The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates

April 27, 2022 | seekingalpha.com

Opiant says pharmacodynamic study shows benefit of its opioid overdose treatment OPNT003

April 27, 2022 | finance.yahoo.com

Opiant Pharmaceuticals Announces Positive Topline Results from Head-to-Head Pharmacodynamic Study Comparing OPNT003, Nasal Nalmefene, to Nasal Naloxone

March 15, 2022 | benzinga.com

Opiant Pharmaceuticals: Q4 Earnings Insights

March 15, 2022 | finance.yahoo.com

Opiant Pharmaceuticals Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive OPNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Opiant Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

OPNT Company Calendar

Last Earnings: 8/11/2022
Today: 10/06/2022
Next Earnings (Estimated): 11/10/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:OPNT
CUSIP: N/A
CIK: 1108924
Web: www.opiant.com
Phone: (310) 598-5410
Fax: 917-322-2105
Employees: 37
Year Founded: 2009

Price Target and Rating

Average Stock Price Forecast: $42.00
High Stock Price Forecast: $42.00
Low Stock Price Forecast: $42.00
Forecasted Upside/Downside: +279.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.07)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $3.01 million
Net Margins: -51.18%
Pretax Margin: -51.16%
Return on Equity: -49.98%
Return on Assets: -31.71%

Debt

Debt-to-Equity Ratio: 0.46
Current Ratio: 9.56
Quick Ratio: 9.56

Sales & Book Value

Annual Sales: $47.78 million
Price / Sales: 1.20
Cash Flow: $0.80 per share
Price / Cash Flow: 13.90
Book Value: $9.92 per share
Price / Book: 1.12

Miscellaneous

Outstanding Shares: 5,160,000
Free Float: 3,865,000
Market Cap: $57.12 million
Optionable: Not Optionable
Beta: 0.57

Social Links

Key Executives

Dr. Roger Crystal M.D. (Age 46)
Pres, CEO & Director
Comp: $1.01M

Mr. David D. O'Toole (Age 63)
Chief Financial Officer
Comp: $624.74k

Dr. Phillip Skolnick D.Sc. (hon) (Age 75)
Ph.D., Chief Scientific Officer
Comp: $638.17k

Mr. Ben Atkins
VP of Communications & Investor Relations

Mr. Brian Gorman
EVP Corp. Devel. & Gen. Counsel

Dr. Mark Heath Ellison Ph.D.
Chief Devel. Officer

Mr. Matthew R. Ruth (Age 52)
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

OPNT Stock - Frequently Asked Questions

Should I buy or sell Opiant Pharmaceuticals stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opiant Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OPNT shares.
View OPNT analyst ratings or view top-rated stocks.
What is Opiant Pharmaceuticals' stock price forecast for 2022?: 2 analysts have issued 12 month price objectives for Opiant Pharmaceuticals' stock. Their OPNT share price forecasts range from $42.00 to $42.00. On average, they predict the company's share price to reach $42.00 in the next twelve months. This suggests a possible upside of 279.4% from the stock's current price.
View analysts price targets for OPNT or view top-rated stocks among Wall Street analysts.
How have OPNT shares performed in 2022?: Opiant Pharmaceuticals' stock was trading at $33.63 at the start of the year. Since then, OPNT shares have decreased by 67.1% and is now trading at $11.07.
View the best growth stocks for 2022 here.
When is Opiant Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 10th 2022.
View our OPNT earnings forecast.

How were Opiant Pharmaceuticals' earnings last quarter?: Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) posted its quarterly earnings data on Thursday, August, 11th. The technology company reported ($2.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.29) by $1.02. The technology company earned $3.89 million during the quarter, compared to analysts' expectations of $5.37 million. Opiant Pharmaceuticals had a negative trailing twelve-month return on equity of 49.98% and a negative net margin of 51.18%.
What other stocks do shareholders of Opiant Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Opiant Pharmaceuticals investors own include Cara Therapeutics (CARA), AcelRx Pharmaceuticals (ACRX), Sangamo Therapeutics (SGMO), Synchrony Financial (SYF), Vodafone Group Public (VOD), Agenus (AGEN), Aldeyra Therapeutics (ALDX), Aurinia Pharmaceuticals (AUPH), Corbus Pharmaceuticals (CRBP) and CyberArk Software (CYBR).
What is Opiant Pharmaceuticals' stock symbol?: Opiant Pharmaceuticals trades on the NASDAQ under the ticker symbol "OPNT."
How do I buy shares of Opiant Pharmaceuticals?: Shares of OPNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Opiant Pharmaceuticals' stock price today?: One share of OPNT stock can currently be purchased for approximately $11.07.
How much money does Opiant Pharmaceuticals make?: Opiant Pharmaceuticals (NASDAQ:OPNT) has a market capitalization of $57.12 million and generates $47.78 million in revenue each year. The technology company earns $3.01 million in net income (profit) each year or ($4.07) on an earnings per share basis.
How can I contact Opiant Pharmaceuticals?: Opiant Pharmaceuticals' mailing address is 233 WILSHIRE BLVD. SUITE 280, SANTA MONICA CA, 90401. The official website for the company is www.opiant.com. The technology company can be reached via phone at (310) 598-5410, via email at investor.relations@opiant.com, or via fax at 917-322-2105.

This page (NASDAQ:OPNT) was last updated on 10/6/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Opiant Pharmaceuticals - OPNT Stock Forecast, Price & News

Opiant Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows